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According to the amyloid hypothesis, Alzheimer Disease results from the accumulation
beyond normative levels of the peptide amyloid-β (Aβ). Perhaps because of its pathologi-
cal potential, Aβ and the enzymes that produce it are heavily regulated by the molecular
interactions occurring within cells, including neurons.This regulation involves a highly com-
plex system of intertwined normative and pathological processes, and the sex hormone
estrogen contributes to it by influencing the Aβ-regulation system at many different points.
Owing to its high complexity, Aβ regulation and the contribution of estrogen are very dif-
ficult to reason about. This report describes a computational model of the contribution of
estrogen to Aβ regulation that provides new insights and generates experimentally testable
and therapeutically relevant predictions. The computational model is written in the declar-
ative programming language known as Maude, which allows not only simulation but also
analysis of the system using temporal-logic. The model illustrates how the various effects
of estrogen could work together to reduce Aβ levels, or prevent them from rising, in the
presence of pathological triggers. The model predicts that estrogen itself should be more
effective in reducing Aβ than agonists of estrogen receptor α (ERα), and that agonists of
ERβ should be ineffective.The model shows how estrogen itself could dramatically reduce
Aβ, and predicts that non-steroidal anti-inflammatory drugs should provide a small addi-
tional benefit. It also predicts that certain compounds, but not others, could augment the
reduction in Aβ due to estrogen. The model is intended as a starting point for a computa-
tional/experimental interaction in which model predictions are tested experimentally, the
results are used to confirm, correct, and expand the model, new predictions are generated,
and the process continues, producing a model of ever increasing explanatory power and
predictive value.
Keywords: Alzheimer disease, amyloid-β, estrogen, computational model, declarative programming, formal
methods, multifactorial process, multi-drug therapy
INTRODUCTION
It is by now well known that the Women’s Health Initiative
found no benefit of estrogen therapy on cognitive function for
post-menopausal women (for reviews, see Anderson et al., 2004;
Espeland et al., 2004). However, a recent evidence-based state-
ment indicates that estrogen therapy may be effective, but it must
be initiated not after menopause but during the perimenopausal
period (North American Menopause, 2012). The lack of unequivo-
cal benefit of estrogen therapy on cognitive function is surprising,
considering that estrogen receptors α and β (ERα and ERβ) are
found throughout the hippocampus and cortex, the two brain
regions most implicated in Alzheimer Disease (AD; Shughrue and
Merchenthaler, 2000), and that estrogen is effective in lowering
brain amyloid-β (Aβ) levels in ovariectomized transgenic mice
that overexpress Aβ (e.g.,Levin-Allerhand et al., 2002; Carroll et al.,
2007). Many other factors are also involved in the pathogenesis of
AD, and it is possible that the failure to take them into account has
obscured the potential benefit of estrogen therapy. The purpose of
this computational modeling study is to begin to account for the
many factors in addition to estrogen that participate in the regula-
tion of Aβ, and to explore ways in which estrogen therapy might be
used more effectively in AD treatment, perhaps by administering
estrogen in conjunction with other agents. The modeling results
can be considered as predictions concerning the effects of admin-
istration of estrogen, ER agonists, and other agents, alone or in
combination, on the level of Aβ. Verification of these predictions
in mouse models of AD would suggest potential new avenues for
the development of pharmacological strategies for AD treatment.
It has been recognized for over a decade that neurodegenerative
diseases such as AD are highly complex and multifactorial (e.g.,
Jellinger, 2003). Meanwhile, the database of experimental findings
on AD grows at an accelerating pace. The sheer size and com-
plexity of the AD database poses a barrier to understanding this
disease. Computational methods are needed to represent the many
interactions that are involved in AD and to simulate and analyze
them in order to gain insight into the disorder, and to generate
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experimentally testable hypotheses that are also relevant to pos-
sible treatments. Recently, powerful computational methods for
simulating and analyzing complex systems have been imported
from computer science into biology (for reviews, see Hlavacek
et al., 2006; Fisher and Henzinger, 2007). These methods, known
as formal methods in computer science, are implemented using
declarative programming languages.
Computationally modeling a system using declarative pro-
gramming permits not only simulation but also analysis of the
system being modeled (Huth and Ryan, 2004). The analysis capa-
bility is essential for reasoning about complex neurodegenerative
disorders such as AD. The declarative programming language used
for the simulations and analyses presented here is known as Maude
(Clavel et al., 2007). Maude has been previously used for modeling
biological systems (Eker et al., 2002; Talcott, 2008), and Maude has
been recently used to model some of the molecular and cellular
interactions that underlie Aβ regulation (Anastasio, 2011). That
model is extended here to include many of the contributions that
estrogen makes to Aβ regulation, and the estrogen-Aβ model will
provide new insights into the multifactorial role of this hormone
in preventing AD.
The estrogen-Aβ model will also be used to explore the possi-
ble benefits of combining other compounds with estrogen, or with
ER agonists, to enhance their ability to reduce Aβ levels. In recog-
nition of AD multifactoriality, some recent experimental studies
have focused on single molecules that act as multitarget drugs
(Bajda et al., 2011; Leon and Marco-Contelles, 2011). Whether
the treatment involves one drug with multiple targets or multiple
drugs with single targets, a consensus is emerging that prevent-
ing or treating a multifactorial disease such as AD will require a
multitarget approach. The computational simulation and analysis
methods presented here are ideal for generating new hypotheses
on multitarget therapies for AD.
MATERIALS AND METHODS
The model is based on the “amyloid hypothesis,” according to
which AD results from the buildup beyond normative levels of
the Aβ peptide (Hardy and Selkoe, 2002). The model concerns
the regulation of Aβ and the transition from the normative to the
pathological state, rather than the state of advanced AD pathol-
ogy in which Aβ levels have been chronically elevated. Although
several possible triggers for Aβ buildup have been proposed, the
model incorporates the subsidiary hypothesis that incipient cere-
brovascular disease (CVD) can cause changes on the molecular
level that dysregulate Aβ and lead to its buildup (Scheibel et al.,
1989; de la Torre, 2009). The effects of estrogen on Aβ regulation
are analyzed with and without the dysregulating effects of CVD. In
order to focus attention on the effects of estrogen on Aβ regulation,
any protection from CVD due to estrogen is disregarded.
BIOLOGICAL BACKGROUND: BASIC Aβ REGULATION
The Aβ peptide occurs in two lengths, Aβ40 and Aβ42, and both are
toxic after they self-aggregate (Walsh and Selkoe, 2007; Di Carlo,
2010). For simplicity here, no distinction will be made between
Aβ40 and Aβ42. The Aβ peptide is produced via cleavage of amyloid
precursor protein (APP) by β-secretase (BACE1 or simply BACE;
Vassar et al., 1999, 2009) followed by γ-secretase (Borchelt et al.,
1996; De Strooper, 2003). Another enzyme,α-secretase (Esch et al.,
1990; Sisodia, 1992; Vingtdeux and Marambaud, 2012) competes
with BACE for APP as its substrate. Cleavage of APP by α-secretase
precludes cleavage of APP by BACE, so that cleavage of APP by α-
secretase precludes Aβ formation. The three secretases, α, β, and
γ, and their substrate, APP, are all membrane proteins.
The γ-secretase enzyme occurs as a complex composed of
presenilin-1 (PS1), presenilin enhancer-2 (PEN2), nicastrin, and
anterior pharynx-defective phenotype-1 (APH1; De Strooper,
2003). APH1 is not represented in the model because little is
known of its regulation, but it is assumed to be present consti-
tutively. Regulation of the other γ-secretase components is repre-
sented in the model. Expression of PS1 and PEN2 is upregulated by
c-Jun, which is phosphorylated by c-Jun N-terminal kinase (JNK)
after JNK is activated by oxidative stress (OS; Tamagno et al., 2008).
In contrast, the extracellular signal regulated mitogen-activated
kinase (ERK) phosphorylates nicastrin and thereby downgrades
its activity (Kim et al., 2006). Buildup of Aβ leads to OS and ERK
activation (Bodles and Barger, 2005; Kim et al., 2006). Thus, Aβ
exerts opposing influences on γ-secretase because it upregulates
two of its components (PS1 and PEN2 via OS, JNK, and c-Jun) but
downgrades one of its components (nicastrin via ERK; Tamagno
et al., 2009).
Both normative and pathological mechanisms regulate BACE.
Two normative loops operate at the RNA level. In one, Aβ upreg-
ulates expression of the BACE antisense transcript (BACEAS-
RNA), which stabilizes the BACE message (BACEmRNA), and
thereby increases BACE protein expression (Faghihi et al., 2008).
In another, Aβ downregulates expression of micro-RNA-107
(BACEmiRNA), which binds to a micro-RNA recognition ele-
ment on BACEmRNA and reduces its translation to BACE (Wang
et al., 2008). Both of these mechanisms increase BACE protein
expression, because Aβ upregulates BACEASRNA, which increases
BACE expression, while Aβ downregulates BACEmiRNA, which
decreases BACE expression. Note that the second loop achieves
increase via decrease of decrease. In general, any pathway or loop
with an even number of decreases will produce increase, just as
in algebra, multiplication of an even number of negatives yields a
positive.
Two pathological loops regulating Aβ are positive because they
involve even numbers of negative interactions. In the first, Aβ
buildup leads to activation of cytokines (Udan et al., 2008; Bul-
garelli et al., 2009), which downregulate expression of the message
for peroxisome proliferator-activated receptor γ (PPARmRNA),
but PPAR downregulates BACEmRNA (Sastre et al., 2006). Thus,
Aβ drives its own buildup by activating cytokines, which suppress
PPAR, which is a suppressor of BACE, which is the enzyme most
responsible for Aβ production. Non-steroidal anti-inflammatory
drugs (NSAIDs) can diminish the effects on Aβ buildup of this
positive feedback loop by upregulating PPAR (Sastre et al., 2006).
The second pathological positive feedback loop involves four
negative interactions. Buildup of Aβ causing OS leads to release
from mitochondria of second mitochondrial-derived activator of
caspase (Smac; Yin et al., 2002). Smac binds to and inhibits XIAP,
a member of the inhibitor of apoptosis protein (IAP) family of
proteins. IAPs inhibit caspase-9. Thus, release of Smac activates
caspase-9 by inhibiting IAPs, thereby releasing caspase-9 from IAP
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inhibition. Activation of caspase-9 leads to activation of caspase-3
leading to apoptosis (Estaquier et al., 2012). Another function of
caspase-3 is to cleave, and thereby inactivate, Golgi-localized γ-
ear-containing ADP-ribosylation-factor binding protein (GGA3;
ADP is adenosine di-phosphate; Tesco et al., 2007). Because GGA3
participates in BACE degradation, caspase-3 activation increases
BACE availability by suppressing its degradation. Thus, around a
positive feedback loop involving OS and the apoptotic pathway,
Aβ drives its own accumulation through two double negatives, the
result of which is to reduce BACE degradation. The degradation-
reducing effects of this loop can be partly diminished by seladin-1,
which decreases caspase-3 activity (Sarajärvi et al., 2009), but
BACE degradation can be augmented by sorting nexin 6 (SNX6;
Muhammad et al., 2008; Small, 2008).
Less is known of the regulation of α-secretase than of γ- or
β-secretase (BACE), but the A disintegrin and metalloprotease 10
and 17 (ADAM10 and ADAM17) family members likely perform
the α-secretase function (Allinson et al., 2003). Either or both
of ADAM10 and ADAM17 may be regulated by protein kinase
C (PKC).
The cerebrovascular insufficiency due to CVD causes both
hypoxia (reduction in oxygen level) and ischemia (reduction in
blood flow), and can alter Aβprocessing by both routes. The reduc-
tion in oxygen level activates hypoxia inducible factor-1-α (HIF1α
or simply HIF), which upregulates BACEmRNA transcription
(Zhang et al., 2007; Guglielmotto et al., 2009). The energy depriva-
tion due to ischemia activates pancreatic endoplasmic reticulum
eIF2-α kinase (PERK), which phosphorylates eukaryotic initia-
tion factor-2-α (eIF2α or simply eIF2), which in turn de-represses
a regulatory element on BACEmRNA and increases BACE protein
translation (O’Connor et al., 2008). The increases in BACE protein
due to CVD lead to increases in Aβ.
The low-density lipoprotein receptor-related protein (LRP) is
involved in multiple but conflicting ways in Aβ processing. It
increases Aβ by binding APP and then making APP more avail-
able to BACE and γ-secretase (Ulery et al., 2000; Yoon et al., 2007;
Lakshmana et al., 2008). In contrast, LRP decreases Aβ by bind-
ing apolipoprotein E (apoE), whereupon the apoE, along with the
Aβ it has bound, is internalized and the Aβ is degraded in the
lysosome (Strittmatter et al., 1993; Manelli et al., 2004). Also, LRP
decreases Aβ by binding it and transcytosing it from the brain into
the peripheral circulation over the brain epithelial cells (BECs)
that compose the blood-brain barrier (Shibata et al., 2000; Deane
et al., 2004). In its transcytotic role LRP works with P-glycoprotein
(Pgp), which transcytoses Aβ out of the brain (Cirrito et al., 2005;
Kuhnke et al., 2007), but it works against the receptor for advanced
glycation end products (RAGE), which transcytoses Aβ in the
opposite direction, into the brain (Deane et al., 2003).
Other molecular mechanisms that regulate Aβ include
reticulon-3 (RTN3) and heparan sulfate, both of which bind BACE
and inhibit Aβ production (Scholefield et al., 2003; He et al., 2004;
Kume et al., 2009). Receptor-associated protein (RAP) binds Aβ
and causes its internalization and degradation (Kanekiyo and Bu,
2009). Enzymes that degrade Aβ include neprilysin (NEP), insulin
degrading enzyme (IDE), and angiotensin-converting enzyme
(ACE; Hu et al., 2001; Sudoh et al., 2002; Kanemitsu et al., 2003;
Hiltunen et al., 2009). The mechanisms outlined in the subsection
are included in a previous model of Aβ regulation (Anastasio,
2011). They represent many of the basic mechanisms of Aβ
regulation that have been described by recent research.
BIOLOGICAL BACKGROUND: INFLUENCES OF ESTROGEN
The main focus of the analysis described here is on the contribu-
tion of estrogen to Aβ regulation. More specifically, the model
represents not fewer than nine different ways in which estro-
gen lowers Aβ levels. The influences of estrogen involve classical
changes in protein expression levels as well as direct effects of
estrogen on cell signaling. These influences are represented in the
model in the context of the basic mechanisms of Aβ regulation
outlined in the previous subsection. As for the basic mecha-
nisms, the estrogen-mediated effects outlined in this subsection
include many of those that have been described by recent research.
Although most animal-based and in vitro experiments employ 17-
β-estradiol rather than other forms of estrogen, the generic term
estrogen will be used here for simplicity.
Estrogen binds and activates both PKCα and PKCδ (Alzamora
et al., 2007). This binding and activation are direct and occur
independently of estrogen binding to estrogen receptors. PKCα,
but not PKCδ, shifts APP processing from BACE to α-secretase
in vitro (Cisse et al., 2011). Such a shift from away from the amy-
loidogenic pathway decreases Aβ levels. These effects were due to
activation of ADAM10 and/or ADAM17 by PKCα, and were not
due to activation of ERK, which activates ADAM17 for functions
other than APP processing.
Estrogen causes astrocytes to increase their PPAR expression
in vitro (Valles et al., 2010), probably via upregulation of PPAR
mRNA. Estrogen also increases seladin-1 mRNA and seladin-1
protein expression in vitro (Benvenuti et al., 2005). This seladin-1
expression reduces the activation of caspase-3 by Aβ (Luciani et al.,
2008). Specific agonists of ERαwere much more effective in upreg-
ulating seladin-1 than specific agonists of ERβ, demonstrating that
estrogen upregulates seladin-1 expression via ERα. Upregulation
of seladin-1 probably occurs via classical mechanisms because the
seladin-1 gene has an estrogen response element (ERE).
Bcl2 (B-cell lymphoma 2) protein family members can be either
pro-apoptotic or anti-apoptotic and together regulate apoptosis
via several mechanisms including release of Smac and activation
of caspase-9 (Youle and Strasser, 2008). Certain pro-apoptotic Bcl2
family members, such as Bim, can block the anti-apoptotic activ-
ity of other Bcl2 family members (Wilson-Annan et al., 2003).
Estrogen increases expression of the anti-apoptotic protein BclxL
(Bclextra-long) in vitro, and this inhibits caspase-mediated pro-
teolysis due to Aβ (Pike, 1999). The estrogen-induced increase in
BclxL probably occurs via classical estrogen gene expression reg-
ulation because the BclxL gene has a putative ERE, and because
the estrogen-induced inhibition of caspase-mediated proteolysis
is prevented by ER blockers.
In vivo, Aβ activates JNK and also downregulates the anti-
apoptotic Bclw and BclxL but upregulates the pro-apoptotic Bim
on both the mRNA and protein levels (Yin et al., 2002; Yao et al.,
2005, 2007). Bclw and BclxL downregulation, and Bim upregula-
tion, probably results from activation of cJun by JNK. Also, Bclw
and BclxL downregulation, and Bim upregulation, are associated
with release of Smac, which results in activation of caspase-9.
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RNA knockdown of Bclw did not lead to release of Smac in the
absence of Aβ, while Bim knockdown substantially reduced but did
not completely eliminate Smac release, suggesting that Aβ causes
Smac release through some combination of different effects. Also
in vivo, estrogen upregulates Bclw and downregulates Bim at both
the mRNA and protein levels (Yao et al., 2007). Estrogen reduces
Aβ-induced phosphorylation of JKN, which reduces but does not
eliminate the effects of activated JNK on Bclw downregulation and
Bim upregulation. It is still uncertain whether estrogen regulates
Bclw and Bim via classical ER mechanisms or via signaling path-
ways. BclxL is probably regulated via classical ER mechanisms (see
previous paragraph).
Estrogen increases superoxide dismutase (SOD1 or simply
SOD) expression in vitro (Rao et al., 2011). The SOD so produced
is effective in limiting damage due to OS. The estrogen-induced
increase in SOD is believed to occur via ERα.
The mRNA for apoE fluctuates with cyclic changes in estrogen
levels in parts of rat hippocampus and hypothalamus (Stone et al.,
1997). Estrogen administration increases apoE mRNA and apoE
protein in mouse and rat brain regions including cortex and hip-
pocampus, but amounts of apoE mRNA upregulated by estrogen
seem to depend on animal strain (Srivastava et al., 1996; Levin-
Allerhand et al., 2001; Wang et al., 2006). Selective activation of
ERα upregulated apoE while selective activation of ERβ down-
regulated apoE in vitro (Wang et al., 2006). It seems that ERα
and ERβ exert antagonistic effects but that ERα overpowers ERβ
since estrogen itself upregulates apoE. Administration of estro-
gen in ovariectomized mice significantly increased LRP in brain
regions including hippocampus and cortex (Cheng et al., 2007).
The increase in LRP seems to be independent of increases in apoE
due to estrogen but the mechanism of LRP increase is unknown.
Estrogen also upregulates Pgp expression (Abuznait et al., 2011).
Activation by estrogen either of ERα or ERβupregulates expres-
sion of NEP mRNA and NEP protein in vitro (Liang et al., 2010).
Activated ERα or ERβexert their influence mainly at EREs on the
NEP gene. Activation of ERα or ERβ by selective drugs increases
NEP expression less than estrogen itself, indicating that the effects
of ERα and ERβ are roughly additive.
COMPUTATIONAL REPRESENTATION AND ANALYSIS
The interactions outlined in the previous two subsections are
diagrammed in Figure 1, and are represented computationally
in a computer program. The diagram is a directed graph, in
which the graph elements are represented as nodes while their
interactions are represented as links. Each node has a label repre-
senting a molecular species (e.g., Aβ) or condition (e.g., OS). Each
node has a variable, numerical value associated with it, and that
value is meant to correspond to an experimentally measureable
quantity. However, due to the qualitative nature of the data on
which the model is based, the correspondence between numer-
ical variable values and experimental measurements is intended
to be proportional rather than exact. To alleviate any ambiguity,
node labels correspond to the actual variable names used in the
computer program, emphasizing the fact that all reported numer-
ical results directly pertain to computer model variables rather
than experimental measurements. Node names reflect accepted
nomenclature as closely as possible within the symbolic limita-
tions of the programming language. Among other limitations, the
programming language does not support Greek lettering, dashes,
or spaces in element names, so accepted nomenclature was altered
accordingly (e.g.,Abeta, BACEmRNA, caspase3). To further distin-
guish model elements from the biological entities they represent,
all element names are printed in monotype font (e.g., Abeta,
BACEmRNA, caspase3).
Most nodes in the diagram are represented as ovals. Internal
nodes both receive and send links, and all internal elements are rep-
resented as oval nodes. Source elements are those with no incom-
ing links. The two main source elements, represented as inverted
triangles, are estrogen and CVD, but many other source ele-
ments are represented as ovals. The single sink node, which sends
no links, is AD, represented as an octagon. Links represent influ-
ence rather than binding. Thus, ERα activation increases seladin-1
mRNA expression by binding an ERE on the seladin-1 gene (see
previous two subsections of Materials and Methods for references),
but this binding is not represented in the model. Instead, the influ-
ence is represented by having ERalpha and seladin1gene
each send a link to seladin1mRNA, since both ERalpha and
seladin1gene influence seladin1mRNA expression.
Links are either positive (arrowhead ending) or negative (tee
ending). Due to the qualitative nature of the data, all links have
absolute value one unless information is available to specify a dif-
ferent value. This occurs in two places in the model. First, one
molecule of LRP binds one molecule of APP so LRP APP bind-
ing helps produce one molecule of Aβ, but one molecule of apoE
can bind multiple molecules of Aβ and so clear multiple Aβ mol-
ecules after the LRP-apoE complex is internalized. Thus, the link
from LRPAPP to Abeta has value +1 but, parsimoniously, the
link from LRPapoE to Abeta has value −2. Second, activation
of ERα and ERβ respectively increase and decrease apoE mRNA
expression, but estrogen, which activates both ERs, produces a net
increase in apoE mRNA expression. Thus, the link fromERalpha
to apoEmRNA has value +2 while the link from ERbeta to
apoEmRNA has value−1.
The interactions depicted in the diagram are all represented
in a computer program written in a specialized meta-language
known as Maude (Clavel et al., 2007). Maude is a declarative pro-
gramming language in which statements are declarations of facts
rather than imperative commands, and for that reason Maude pro-
grams are also referred to as specifications. The main difference
between the two computational approaches is that in an imperative
program, commands execute in a specified order while in a specifi-
cation, declarations execute in an unspecified order provided they
are applicable. Both imperative and declarative programming lan-
guages can be used to create computer models of real systems but,
because the statements in a specification are declarations of facts, a
declarative specification can be used not only to simulate a system
but also to analyze it using the methods of temporal-logic (Huth
and Ryan, 2004). Both simulation and temporal-logic analysis will
be applied here in evaluating the model of the contribution of
estrogen to Aβ regulation (called the estrogen-Aβ model).
A specification in Maude is based on an underlying algebra
characterized by a set of data types and allowed operations on,
and between, those data types (Clavel et al., 2007). Each ele-
ment in the estrogen-Aβ model is represented by an operator that
assigns an integer value to that element. For example, the oper-
ator estrogen(1) assigns the integer value 1 to estrogen
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FIGURE 1 | Schematic diagram of the estrogen-Aβmodel. Model
elements are represented using labels within geometric shapes
(nodes). Each connection (link) leads from an origin element to a
destination element whose level is influenced by that origin element.
Arrowhead or tee endings represent positive or negative influence,
respectively. Estrogen and cerebrovascular disease (CVD) are the main
source elements, but any element with no connections leading to it is a
source element. Alzheimer Disease (AD), with no connections leading
from it, is the only sink element. The other element labels are defined
in the text.
and makes that assignment a State of the system. A concatena-
tion operator allows multiple State expressions to be combined
into a single State expression. Some other operators serve only
as integer constants that are used as thresholds or levels of con-
stitutive expression. Specifically, the operators thrCY, thrERK,
thrOS, and thrAD are the input thresholds for activation of
cytokine, ERK, OS, and AD and they take integer values of 6, 6,
9, and 12, respectively. The operators conBACEmRNA,conBACE,
and conAbeta assign integer baselines (i.e., constitutive expres-
sion levels) of 6 to each of BACEmRNA, BACE, and Abeta. These
thresholds and levels of constitutive expression, combined with
the interaction (i.e., link) values described above, constitute the
full set of parameters of the model. Using these parameters, the
interactions diagrammed in Figure 1, and the interaction descrip-
tions provided in the previous two subsections of Materials and
Methods, the modeling results presented in Results should be
reproducible.
Declarations in Maude are either equations or rules, and
together they describe the system being modeled. Both equations
and rules are based on the underlying algebra and its data types
and allowed operations. The main difference between them is that
applicable equations must execute, but applicable rules may exe-
cute or not. This difference is critical for the ability of Maude to
analyze a system because she can follow not just one but every
possible order of applicable rule executions and thereby explore
the entire model state space. On each path through the state space,
Maude executes an applicable rule and then executes every equa-
tion made applicable by execution of that rule. She then executes
another applicable rule, but the order of rule executions is differ-
ent for each path. By constructing and then searching all possible
paths through the state space, Maude can evaluate temporal-logic
propositions such as whether one specific state always leads to
another specific state, or whether one specific state pertains only
until another specific state occurs, and so on (Huth and Ryan,
2004; Clavel et al., 2007).
The integer values assigned by the operators to model elements
are kept non-negative. For many elements, this is accomplished by
treating their integer levels simply as binary (i.e., their levels are
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of the integer data type but they are restricted to values of 0 or
1). Other elements are allowed to take multiple integer levels but
they are kept non-negative through logic and/or by providing one
of the baseline, constitutive levels of expression so that negative
inputs do not force their levels to go below zero. Source nodes,
which receive no inputs, have their levels set at the beginning of a
simulation or analysis. Through the many forward and recurrent
(i.e., feedback) links in the model, whose effects are described by
rules and equations, the levels of the source and internal nodes
affect the levels of the other internal nodes and, ultimately, the
sink node.
The Maude specification for the estrogen-Aβ model is called
ALZHEIMERE, where the last E stands for estrogen. Each decla-
ration in ALZHEIMERE describes how the level of one element
is affected by the levels of its input elements. Only three decla-
rations in the model are rules. These are the declarations that
describe the activation of ERalpha, ERbeta, and PKCalpha
by estrogen. For example, Maude code for the declaration that
determines the activation of ERalpha is shown below (all Maude
code is written in monotype font).
crl [ERalphaAct]:estrogen(X1) ERalphaAg(X2)
ERalpha(Y) =>
estrogen(X1) ERalphaAg(X2)
ERalpha(if X1 > 0 or
X2 > 0 then 1 else 0 fi)
if Y =/= if X1 > 0 or
X2 > 0 then 1 else 0 fi.
In this rule, called ERalphaAct, the levels of estrogen,
the ERα agonist ERalphaAg, and ERalpha are represented
by integer variables X1, X2, and Y, respectively. The rule speci-
fies that the levels of estrogen and ERalphaAg remain the
same but the level of ERalpha goes to 1 if either X1 or X2 is
greater than 0, or goes to 0 if neither X1 nor X2 is greater than
0. Note that the rule is conditional (crl), so that the level of
ERalpha can change to 1 or 0 but will not be reassigned 1 or 0
if it had that value already. The conditionality of the rule makes
it applicable only if executing it will change the value assigned
to ERalpha. Note also that the conditional rule limits the value
of ERalpha to binary values. The conditional rules that deter-
mine the activation of ERbeta and PKCalpha (not shown) are
similar.
All of the other declarations in ALZHEIMERE are equa-
tions and, more specifically, conditional equations. For exam-
ple, the conditional equation (ceq) that determines the level of
BACEmRNA expression, called BACEmessage, is shown below.
ceq [BACEmessage]:BACEgene(G) BACEASRNA(X1)
HIF(X2) PPAR(Y)
BACEmRNA(Z) =
BACEgene(G) BACEASRNA(X1)
HIF(X2) PPAR(Y)
BACEmRNA(((conBACEmRNA
+ X1 + X2) - Y) * G)
if Z =/= ((conBACEmRNA
+ X1 + X2) - Y) * G.
In this equation the levels of BACEgene, BACEASRNA, HIF,
PPAR, and BACEmRNA are represented by the integer variables G,
X1,X2,Y, and Z, respectively. The equation specifies that the levels
of BACEgene,BACEASRNA,HIF, and PPAR remain unchanged
but the level of BACEmRNA equals the sum of its positive inputs
X1 and X2 and its constitutive level conBACEmRNA, minus its
negative input Y, and this difference is multiplied by G, which is 1
if the gene is present but 0 if it is absent. The conditionality of the
equation makes it applicable only if executing it will change the
value assigned to BACEmRNA.
The rules and equations need to be conditional to prevent
them from executing if doing so would not change the value
of any element. Without such a condition, the declaration that
determines the level of any element, whether equation or rule,
would continue executing ad infinitum, simply replacing the value
assigned by its operator with the identical value. With such con-
ditions, declarations do not execute unless doing so would change
the value of an element, and the specification terminates when
no further changes to element values can be made. The Maude
specification ALZHEIMERE terminates for all start configura-
tions (i.e., assignments of source node values) that are reported
in Results.
In the context of declarative programming, temporal-logic
analysis is also known as model checking. Model checking for
Maude specification ALZHEIMERE is carried out using a sepa-
rate specification called MC-ALZHEIMERE. The main function
of MC-ALZHEIMERE is to define a set of properties of interest
that can be verified through executions of rules and equations
in ALZHEIMERE. For example, the following (non-conditional)
equation indicates when the property NEPeq3 is true.
eq AM(S NEP(3)) |= NEPeq3 = true.
(where |= is the logical connector “satisfies”). The operator AM
is a “wrapper” and the term AM(S NEP(3)) simply defines
the state of the system when NEP is at level 3 and all other ele-
ments, at whatever levels, are subsumed under the variable S. The
equation specifies that the system with NEP at level 3 satisfies
the proposition that NEPeq3 is true, regardless of other element
levels. In executing this equation in MC-ALZHEIMERE, Maude
will determine, given some initial configuration of the model (i.e.,
assignments of source node values) and rule and equation execu-
tions in ALZHEIMERE, that NEPeq3 is true, or it will be unable
to execute further rules and equations in ALZHEIMERE and will
“deadlock” without determining that NEPeq3 is true. Temporal-
logic analysis involves verification of properties individually or
combined into more complex logical statements. Both simulation
and temporal-logic analysis will be used to generate results on, and
to derive predictions from, the estrogen-Aβ model.
RESULTS
The Maude specificationALZHEIMERE computationally describes
the interactions depicted in Figure 1, which represent many of the
recently identified contributions that estrogen makes to the regu-
lation of Aβ. By representing these interactions the Maude model
can indicate what they mean in the aggregate. More specifically,
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the model can indicate what effects different combinations of hor-
mone or estrogen receptor agonists and other drugs might have
on the level of Aβ, whether under conditions of low estrogen alone
or exacerbated by mild CVD. The Maude model, like any model,
is a hypothesis that needs to be verified experimentally, and many
of the results of model simulation and analysis reported in this
section can be taken as predictions of the model (see Discussion).
Simulations begin by finding the normal, baseline level of Aβ in
the model. This is done by setting all of the source elements to their
normative levels (including the normative level of estrogen) and
then letting Maude execute all applicable equations and rules until
a terminal state is reached. In Maude, a rule execution is known as
a “rewrite” while an equation execution is known as a “reduction.”
Since rule executions (i.e., rewrites) can make equations applicable
and so lead to equation executions (i.e., reductions), both rule and
equation executions can be produced using rewrite commands. A
command to produce twenty rewrites in the Maude specification
ALZHEIMERE from the normative start-state is shown below.
rewrite [20] in ALZHEIMERE : PPARgene(1)
PS1gene(1) PEN2gene(1) NICgene(1)
seladin1gene(1) GGA3gene(1) APPgene(1)
LRPgene(1) apoEgene(1) Pgpgene(1)
BACEASgene(1) BACEmigene(1) BACEgene(1)
NEPgene(1) BclxLgene(1) Bclwgene(1)
Bimgene(1) estrogen(1) SNX6(1) RAGE(1)
hepSul(1) RTN3(1) RAP(1) IDE(1) ACE(1)
CVD(0) NSAID(0) HIFblock(0) caspBlock(0)
ERKblock(0) PERKblock(0) ERalphaAg(0)
ERbetaAg(0) hypoxia(0) HIF(0) ischemia(0)
PERK(0) eIF2(0) cytokine(0) PPARmRNA(0)
PPAR(0) OS(0) JNK(0) cJun(0) SOD(0) ERK(0)
PS1mRNA(0) PS1(0) PEN2mRNA(0) PEN2(0)
nicastrin(0) gammaSec(0) PKCalpha(0)
alphaSec(0) Smac(0) XIAP(0) caspase9(0)
caspase3(0) seladin1mRNA(0) seladin1(0)
GGA3(0) APP(0) Abeta(0) AD(0) LRPmRNA(0)
LRP(0) apoEmRNA(0) apoE(0) LRPapoE(0)
LRPAPP(0) BECLRP(0) PgpmRNA(0) Pgp(0)
BACEASRNA(0) BACEmiRNA(0) BACEmRNA(0)
BACE(0) NEPmRNA(0) NEP(0) BclxLmRNA(0)
BclxL(0) BclwmRNA(0) Bclw(0) BimmRNA(0)
Bim(0) ERalpha(0) ERbeta(0)
The order of operators in this list is arbitrary and is, in any case,
determined internally by Maude. In the normative start-state, all
genes (e.g., APPgene) and all endogenous factors (e.g., SNX6)
are present, but all agonists (e.g., ERalphaAg) and other drugs
(e.g.,NSAID) are absent. Also in the normative stateestrogen is
present but CVD is absent. Note that a source element is present or
absent when its level is 1 or 0, respectively. In the start-state the lev-
els of all of the internal nodes, including Abeta, and the sink node
AD, are set to 0. Twenty rewrites is more than enough to ensure
that all applicable rules will execute. The result of rewriting from
the normative start-state in Maude specification ALZHEIMERE is
shown below.
result State: CVD(0) hypoxia(0) HIF(0)
HIFblock(0) ischemia(0) PERK(0) PERKblock(0)
eIF2(0) cytokine(0) PPARgene(1) PPARmRNA(2)
PPAR(2) NSAID(0) OS(0) JNK(0) cJun(0) SOD(1)
ERK(0) ERKblock(0) PS1gene(1) PS1mRNA(1)
PS1(1) PEN2gene(1) PEN2mRNA(1) PEN2(1)
NICgene(1) nicastrin(2) gammaSec(1)
PKCalpha(1) alphaSec(1) Smac(0) XIAP(0)
caspase9(0) caspase3(0) caspBlock(0)
seladin1gene(1) seladin1mRNA(1) seladin1(1)
GGA3gene(1) GGA3(2) SNX6(1) APPgene(1)
APP(1) Abeta(2) AD(0) LRPgene(1) LRPmRNA(2)
LRP(2) apoEgene(1) apoEmRNA(2) apoE(2)
LRPapoE(2) LRPAPP(1) BECLRP(2) Pgpgene(1)
PgpmRNA(2) Pgp(2) RAGE(1) BACEASgene(1)
BACEASRNA(2) BACEmigene(1) BACEmiRNA(1)
BACEgene(1) BACEmRNA(6) BACE(8) hepSul(1)
RTN3(1) RAP(1) IDE(1) ACE(1) NEPgene(1)
NEPmRNA(3) NEP(3) BclxLgene(1) BclxLmRNA(2)
BclxL(2) Bclwgene(1) BclwmRNA(1) Bclw(1)
Bimgene(1) BimmRNA(1) Bim(1) estrogen(1)
ERalpha(1) ERbeta(1) ERalphaAg(0)
ERbetaAg(0)
Again the order of operators in the list is arbitrary. The levels of the
source elements remain unchanged while the levels of many, but
not all, of the internal elements have changed. Note, for exam-
ple, that with CVD absent, neither hypoxia nor ischemia
occurs. Consequently, neither HIF nor PERK is activated. With
estrogen present, both ERalpha and ERbeta are activated.
Also, with CVD absent and estrogen present, OS does not
occur and cytokine, JNK, ERK, and caspase3 are not acti-
vated. In this, the normative baseline state, the heavily regulated
BACEmRNA, BACE, and Abeta take integer values of 6, 8, and
2, respectively, and AD does not occur. These normative results
are shown in Row 1 of Table 1. It is imperative to reiterate (see
Computational Representation and Analysis) that the levels of the
various model elements are meant to be proportional to levels of
real molecules, and that changes in model element levels due to
changes in model inputs constitute the relevant modeling results.
LOWERING Aβ IN THE ABSENCE OF ESTROGEN AND THE ABSENCE OF
CVD
Table 1 tabulates the results of model simulations (i.e., rewrites in
ALZHEIMERE) initiated from many different start configurations
but all in the absence of CVD. Whereas Row 1 of Table 1 shows the
normal, baseline state of the model, Row 2 shows the consequences
for the model of removing estrogen. Neither ERalpha nor
ERbeta are activated in the absence of estrogen and in the
absence of any estrogen receptor agonists. This lack leads to the
activation of OS and caspase3. That and other changes in inter-
nal element levels lead to increases of BACEmRNA from 6 to 8, of
BACE from 8 to 11, and of Abeta from a normative level of 2 to
11. Because the model is focused on Aβ regulation, and because
the actual relationship between Aβ and AD is still incompletely
understood, the Aβ threshold at which AD occurs is set arbitrarily
in the model. This threshold is set at the relatively high level of 12,
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and AD occurs only if Abeta is strictly greater than 12, so AD does
not occur in the absence of both estrogen and CVD (Row 2 of
Table 1). The more important finding in this case is the change in
Abeta, and the increase in Abeta from 2 to 11 is substantial in
the context of the model.
Considering the many ways in whichestrogen limitsAbeta
production in the model, this drastic rise in Abeta level in
the absence of estrogen is not surprising, even without CVD.
Through the ERalpha and ERbeta receptors, estrogen
reduces BACEmRNA expression by increasing PPAR expression
(via upregulation of PPARmRNA), and the decrease inBACEmRNA
leads to a decrease inBACE and so inAbeta. Also through its clas-
sical receptors,estrogendecreasesAbetaby increasing expres-
sion of LRP, apoE, NEP, and Pgp. Less directly, estrogen
reduces Abeta because it reduces OS by upregulating SOD, and
suppresses caspase3 activation by upregulating seladin1
and BclxL. Because OS and caspase3 activation can augment
BACE levels, estrogen reduces BACE and so reduces Abeta by
reducing OS and caspase3 activation. Through its activation
of PKCalpha, estrogen further reduces Abeta by activat-
ing alphaSec, which diverts APP away from the amyloidogenic
pathway. Due to the presence of numerous positive feedback loops
by which Abeta upregulates BACE and so drives its own accu-
mulation,estrogen can, essentially, reduce Abeta by reducing
this positive feedback drive. Thus, estrogen exerts downward
pressure on Abeta in about 10 different ways in the model, and
so the dramatic upraising of Abeta in the absence of estrogen
is not surprising.
The rest of Table 1 is concerned with the question of how vari-
ous drugs, alone or in combination, could help keep Abeta levels
down in the absence of estrogen (the state of 0 estrogen in
the model corresponds to a worst-case post-menopausal scenario).
In the model the effect of NSAID is to augment the expres-
sion of PPARmRNA and so of PPAR itself (other possible effects
of NSAIDs are not represented for simplicity). Because PPAR
suppresses BACEmRNA expression, NSAID reduces BACEmRNA
and, consequently, also reduces BACE and Abeta. With links of
absolute value 1 for the interactions that mediate these NSAID
effects, activation of NSAID (i.e., changing NSAID level from 0
to 1) results in a decrease of 1 for each of BACEmRNA, BACE, and
Abeta (compare Rows 3 and 2 of Table 1).
The function of HIFblock in the model is to keep HIF at
level 0 even in the presence of hypoxia. In the model,hypoxia
is brought about by CVD and hypoxia does not occur without
it. For the simulations whose results are listed in Table 1, CVD is
absent, hypoxia does not occur, and HIF is not activated, so
blocking HIF using HIFblock should have no effect. Indeed it
does not (compare Rows 4 and 2 of Table 1). The presence of
HIFblock does not reduce Abeta from its high level of 11 in
the absence of estrogen.
The function of caspBlock in the model is, likewise, to
keep caspase3 at level 0 despite activation of the pro-apoptotic
pathway. This pathway is activated by OS in the model and is
regulated by many factors, some of which are under the control
of estrogen (e.g., BclxL and seladin1). The occurrence
of OS in the model is determined by the level of Abeta and by
the activation of cytokine, which itself depends on the level
of Abeta, and the rise in Abeta resulting from the absence of
estrogen is enough to cause OS and so activate caspase3. In
this case blocking caspase3 using caspBlock should have a
beneficial effect. Indeed it does (compare Rows 5 and 2 of Table 1).
Note that caspase3 exerts its effects on BACE rather than on
BACEmRNA, so the presence of caspBlock does not change the
level of BACEmRNA but it decreases the levels both of BACE and
of Abeta by 1.
Two factors that independently produce the same effect could
produce a greater effect in combination, especially if they work via
different pathways. This is the case for NSAID and caspBlock
(compare Rows 6 and 2 of Table 1). Applying NSAID and
caspBlock together reduces BACEmRNA from 8 to 7, BACE
from 11 to 9, and Abeta from 11 to 9. Since HIF is acti-
vated only by CVD and CVD is not present in this set of sim-
ulations, HIFblock, even in combination with other factors,
should provide no benefit. As expected, in the absence of both
estrogen and CVD, HIFblock in combination with NSAID
and caspBlock is not more effective in reducing Abeta than
are NSAID and caspBlock without HIFblock (compare
Rows 7 and 6 of Table 1). These simulations suggest than in a state
of very low estrogen, the rise in Aβ could be slightly offset using
an NSAID-class drug that promotes PPAR expression or a com-
pound that blocks caspase-3 activation, and that their combination
would be more effective than either one alone. This set of simu-
lations further suggests that, in the absence of CVD, compounds
that block HIF activation would not be effective in lowering Aβ
levels consequent to estrogen depletion, even in combination with
other compounds that work via different pathways.
An alternative to estrogen therapy is to administer drugs that
act as agonists for specific estrogen receptors. This alternative is
explored computationally using the model, and the results are
tabulated in the second and third blocks of Table 1. Again, both
estrogen and CVD are absent. The simulations show that the
administration of an agonist of ERβ (ERbetaAg) provides no
benefit in the model. The effect of ERbetaAg alone is to decrease
BACEmRNA from 8 to 7 and to decrease BACE from 11 to 10,
but ERbetaAg alone does not decrease Abeta (compare Rows
8 and 2 of Table 1). This initial result exposes the main drawback
of ERbetaAg. Although it provides some of the same benefits
as estrogen, ERbetaAg causes a decrease in apoE. Specif-
ically, apoE is expressed at level 1 without estrogen but at
level 0 with the addition of ERbetaAg. Because ERbetaAg sup-
pressesapoE it cannot lowerAbetadespite loweringBACEmRNA
and BACE. In the model, ERbetaAg provides no benefit by
itself.
As was the case previously without estrogen and without
CVD, NSAID and caspBlock both reduce Abeta in the pres-
ence of ERbetaAg but HIFblock does not. Again as in the
previous case,NSAID and caspBlockwork better together than
separately but HIFblock remains ineffective even in combina-
tion with NSAID and caspBlock (see Rows 9 through 13 in
Table 1). Because it reduces the level of apoE, ERbetaAg pro-
vides no benefit over NSAID and caspBlock despite lowering
bothBACEmRNA andBACE. The model suggests that ERβ agonists
would not be effective replacements for estrogen for the purpose
of Aβ reduction.
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The situation is dramatically different with administration of
an ERα agonist (ERalphaAg). The presence of ERalphaAg
alone reduces BACEmRNA from 8 to 6, BACE from 11 to 8, and
Abeta from 11 to 4 (compare Rows 14 and 2 of Table 1). There
are three reasons why ERalphaAg alone reduces Abeta sub-
stantially while ERbetaAg alone does not reduce Abeta at all.
First, ERalphaAg increases apoE while ERbetaAg decreases
it. Specifically, apoE is expressed at level 1 without estrogen,
is expressed at level 0 with the addition of ERbetaAg alone, but
is expressed at level 3 with the addition of ERalphaAg alone.
Second, ERalphaAg increases seladin1, but ERbetaAg has
no effect on it. Third, the combined effects of ERalphaAg,
including increases in apoE, seladin1, NEP, and Pgp, are
enough to bring Abeta below the threshold at which it acti-
vates cytokine and OS. By preventing OS in the absence of
estrogen, ERalphaAg breaks the main, pathological positive
feedback loop by which Abeta drives its own accumulation, and
that keeps Abeta levels down.
As before in the absence of estrogen, or with ERbetaAg,
NSAID is also able to reduce each of BACEmRNA, BACE, and
Abeta by 1 in combination with ERalphaAg (compare Rows
15 and 14 of Table 1). Again as before in the absence of CVD,
HIFblock is ineffective in reducing Abeta (or BACEmRNA
or BACE) with ERalphaAg because HIF is not activated
unless CVD is present to cause hypoxia (compare Rows 16
and 14 of Table 1). Because ERalphaAg, like estrogen
itself, increases seladin1, and because seladin1 suppresses
caspase3, caspBlock is also ineffective in reducing Abeta
(or BACEmRNA or BACE) with ERalphaAg (compare Rows 17
and 14 of Table 1). Thus, in the absence of estrogen and CVD,
a combination of ERalphaAg and NSAID is capable of bringing
Abeta back down to 3, which is close to the normative level of 2
(compare Rows 18 and 1 of Table 1). The model suggests that, in
the post-menopausal state of low estrogen, the level of Aβ could
be reduced almost as effectively with a combination of an ERα
agonist and an NSAID as with estrogen itself.
LOWERING Aβ IN THE PRESENCE OF CVD
Lack of estrogen leads to a pronounced upraising of Abeta in
the model, as described in the previous subsection and as shown
in Rows 1 and 2 of Table 1. This is exacerbated by CVD, as shown
in Row 1 of Table 2. In the absence of estrogen but in the pres-
ence of CVD, BACEmRNA rises from a normative level of 6 to 9,
BACE from a normative 8 to 13, and Abeta from a normative 2
to 13 (compare Row 1 of Table 1 with Row 1 of Table 2). With
the AD threshold set arbitrarily at 12 in the model, the absence
of estrogen combined with the presence of CVD raises Abeta
enough to cause AD. The obvious implication here is that CVD
would be expected to exacerbate the Aβ accumulation due to low
estrogen, especially since CVD raises Aβ via pathways different
from those by which estrogen lowers it (see Figure 1).
As before, in the absence of both estrogen and CVD (Rows
3 and 5 of Table 1), NSAID and caspBlock are also effective in
lowering Abeta in the absence of estrogen but in the presence
of CVD (Rows 2 and 4 of Table 2). Furthermore, because CVD, and
the hypoxia it causes are present,HIFblock is effective in low-
ering Abeta in this case (Row 3 of Table 2) whereas it was not
in the case of no CVD (Row 4 of Table 1). Also with estrogen
absent but CVD present, NSAID, HIFblock, and caspBlock
are more effective in combination than separately (Rows 5 through
8 of Table 2). Specifically, in the absence of estrogen but in the
presence of CVD, each of NSAID, HIFblock, and caspBlock
can lower BACE and Abeta by 1 and their effects are additive.
Although each of NSAID and HIFblock can lower BACEmRNA
by 1, caspBlock has no effect on BACEmRNA. The lack of
effect of caspBlock on BACEmRNA results because caspase3
bypasses BACEmRNA and works directly to increase BACE by sup-
pressing GGA3. These simulations suggest than in a state of very
low estrogen combined with incipient CVD, the rise in Aβ could
be slightly offset using an NSAID-class drug that promotes PPAR
expression, or a compound that blocks HIF, or a compound that
blocks caspase-3 activation, and that administration of any two,
or all three, of the compounds in combination would be more
effective than any one of the three administered alone.
Although the level of Abeta is a bit higher with estrogen
absent but CVD present, the effects of ERbetaAg in this case
(Rows 9 through 16 of Table 2) are similar to those with
estrogen and CVD both absent (Rows 8 through 13 of Table 1)
in the sense that ERbetaAg can lower BACEmRNA by 1, and
thereby lower BACE by 1, but it has no net effect on Abeta.
As with estrogen absent but CVD present (Rows 1 through
8 of Table 2), each of NSAID, HIFblock, and caspBlock
can lower BACE and Abeta by 1 and their effects are addi-
tive, and NSAID and HIFblock lower BACE by lowering
BACEmRNA while caspBlock lowers BACE without also low-
ering BACEmRNA (Rows 9 through 16 of Table 2). Because
ERbetaAg, likeestrogen itself, reducesBACEmRNA viaPPAR,
both BACEmRNA and BACE are lower, under all combina-
tions of NSAID, HIFblock, and caspBlock, in the pres-
ence of ERbetaAg when estrogen is absent but CVD is
present (compare Rows 9 through 16 with Rows 1 through 8
of Table 2). However, because ERbetaAg administered in the
absence of estrogen reduces apoE from 1 to 0, the net effect
of ERbetaAg on Abeta is 0. The implication of these model-
ing results is that, under conditions of low estrogen and incipient
CVD, administration of an ERβ agonist would provide no benefit
in terms of lowering Aβ.
In sharp contrast to the overall lack of benefit of ERbetaAg,
administration of ERalphaAg provides a substantial benefit
in terms of lowering Abeta with estrogen absent but CVD
present (Rows 17 through 22 of Table 2), as it had previously with
estrogen andCVDboth absent (Rows 14 through 18 of Table 1).
Addition of ERalphaAg alone reduces BACEmRNA from 9 to 8,
BACE from 13 to 11, and Abeta from 13 to 7 (compare Rows 17
and 1 of Table 2). The sharp drop in Abeta occurs because the
suppression of Abeta production, and the promotion of Abeta
elimination, due to ERalphaAg are enough to prevent Abeta
from rising about the threshold for activation of OS, and this
breaks the main, pathological positive feedback loop by which
Abeta drives its own accumulation in the model. OS is among
the factors that activate caspase3, while seladin1 is among
the factors that inactivate it, so by preventing OS and promoting
seladin1,ERalphaAg is able to suppresscaspase3. For this
reason,caspBlock does not provide additional benefit in terms
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of lowering Abetawhen ERalphaAg is added under conditions
in which estrogen is absent but CVD is present (compare Rows
20 and 17 of Table 2).
Although caspBlock is ineffective in combination with
ERalphaAg under conditions in which estrogen is absent
but CVD is present, each of NSAID or HIFblock is even more
effective in combination with ERalphaAg than either is alone
(compare Rows 17 through 19 with Rows 1 through 3 in Table 2).
Specifically, with estrogen absent but CVD present, NSAID or
HIFblock alone reduces Abeta from 13 to 12 (Rows 1 through
3 of Table 2), but in combination with ERalphaAg, NSAID,
or HIFblock reduces Abeta from 7 to 5 (Rows 17 through
19 of Table 2). Thus, with estrogen absent but CVD present,
NSAID or HIFblock alone reduces Abeta by 1, but either
reduces Abeta by 2 in combination with ERalphaAg (com-
pare Rows 17 through 19 with Rows 1 through 3 in Table 2). The
reason for the larger drop is that NSAID or HIFblock in com-
bination with ERalphaAg lowers Abeta enough to prevent the
activation of cytokine, which indirectly increases BACE and so
increases Abeta. This synergistic (more than additive) effect of
ERalphaAg combined with either NSAID or HIFblock is due
to a threshold effect, specifically a failure to cross the cytokine
threshold. Similarly, the dramatic effect of ERalphaAg alone,
which reduces Abeta from 11 to 4 with estrogen and CVD
both absent (compare Rows 2 and 14 of Table 1), and reduces
Abeta from 13 to 7 with estrogen absent but CVD present
(compare Rows 1 and 17 of Table 2), is also due to a threshold
effect, specifically a failure to cross the OS threshold.
Under conditions in which estrogen is absent but CVD is
present, and ERalphaAg is administered in combination either
with NSAID or HIFblock, neither the OS nor the cytokine
thresholds will be crossed, and Abetawill be held at the relatively
low level of 5 (Rows 18 and 19 in Table 2). Under these same con-
ditions, administration of ERalphaAg in combination with both
NSAID and HIFblock will further reduce Abeta to 4 (Row 21
in Table 2). Administration of caspBlock confers no additional
benefit (Row 22 of Table 2). These results suggest that, under con-
ditions of low estrogen and incipient CVD, administration of an
ERα agonist alone or combined with an NSAID-class drug that
promotes PPAR expression and/or a compound that blocks HIF,
would be effective in lowering Aβ, but that a compound that blocks
caspase-3 activation would confer no additional benefit.
While ERalphaAg alone, and especially in combination with
NSAID and HIFblock, produces a substantial reduction in
Abeta when estrogen is absent but CVD is present, adminis-
tration of estrogen itself is even more effective. Administration
of estrogen in the presence of CVD lowers BACEmRNA from
9 to 7, BACE from 13 to 10, and Abeta from 13 to 4 (compare
Rows 1 and 23 of Table 2). This dramatic lowering of Abeta is
a compound threshold effect, since administration of estrogen
in the presence of CVD lowers Abeta below the thresholds of
activation of both OS and cytokine. Under these conditions,
administration of NSAID or HIFblock results in further reduc-
tion of BACEmRNA,BACE, and Abeta each by 1 (Rows 24 and 25
of Table 2). Because estrogen both prevents OS and promotes
seladin1 it is able to suppress caspase3, so administration
of caspBlock provides no additional benefit in the presence of
both estrogen and CVD (Row 26 in Table 2). When Abeta
is below both the OS and cytokine thresholds the effects of
NSAID and HIFblock are additive, rather than synergistic, so
that administration of NSAID and HIFblock together results
in a further reduction of BACEmRNA, BACE, and Abeta each
by 1 (Row 27 of Table 2). As expected, caspBlock provides no
additional benefit in terms of Abeta reduction in the presence
of estrogen, even if administered in combination with NSAID
and HIFblock (Rows 26 and 28 of Table 2). In the presence of
CVD, the combined administration of estrogen, NSAID, and
HIFblock brings Abeta from the AD-inducing level of 13 all
the way back to the normative level of 2 (compare Rows 1 and
27 of Table 2). These modeling results suggest the possibility that,
under conditions of very low estrogen and incipient CVD, the
level of Aβ could be brought back to normal with a combination
of an NSAID-class drug that promotes PPAR expression and a
compound that blocks HIF, in conjunction with estrogen itself.
ERα AGONISTS MAY BE LESS EFFECTIVE THAN ESTROGEN ITSELF IN
LOWERING Aβ
Using NSAID and HIFblock in the presence of CVD,
ERalphaAg can reduce Abeta to 4, but estrogen itself
can reduce Abeta all the way back to the normative level of 2
(compare Rows 21 and 27 of Table 2). Although estrogen by
itself can prevent cytokine activation in the presence of CVD,
ERalphaAg can also prevent cytokine activation in combi-
nation with NSAID and HIFblock (note that estrogen or
ERalphaAg alone can prevent OS as shown in Rows 17 and 23
of Table 2). Furthermore, apoE reaches level 2 with estrogen
but reaches level 3 with ERalphaAg, so ERalphaAg pro-
vides a benefit over estrogen itself in terms of apoE. Why
then is estrogen able to reduce Abeta even further than
ERalphaAg? Temporal-logic analysis can be used to answer that
question in the model.
Temporal-logic analysis begins by defining properties of inter-
est, and then checking the value of those properties alone or
combined into propositions (see Materials and Methods). Some
properties that are useful for this analysis are: ERaACT, ERbACT,
PKCeq1, and AbEQ2 (other properties also used have simi-
lar nomenclature). The properties ERaACT and ERbACT are
true when ERalpha or ERbeta, respectively, are activated by
estrogen. The properties PKCeq1 and AbEQ2 are true when
PKCalpha is 1 or when Abeta is 2, respectively. The value of
these (and other) properties alone or combined into propositions
can be checked under specific sets of conditions. To determine
why estrogen, in combination with NSAID and HIFblock,
can bring Abeta to level 2 in the presence of CVD, the analy-
sis takes place under conditions in which estrogen, NSAID,
HIFblock, and CVD are all present.
In the Maude specification ALZHEIMERE, which specifies
the estrogen-Aβ model, estrogen activates ERalpha and
ERbeta, and it also bringsPKCalpha to level 1. Because all three
of these interactions are specified as rules, temporal-logic analysis
can be used to explore the consequences of these interactions in all
possible orders of occurrence. Some results of the temporal-logic
analysis are shown in Table 3. To begin, temporal-logic analysis
is used to check the value of the proposition ERaACT⇒ AbEQ2
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Table 3 | Using temporal-logic to check the model in the presence of
CVD when estrogen, NSAID, and HIFblock, but not caspBlock, are
available.
# Proposition Value
1 Activation of ERalpha implies Abeta equals two False
2 Activation of ERalpha and ERbeta implies Abeta equals two False
3 Activation of ERalpha, and PKCalpha equals one, imply
Abeta equals two
False
4 Activation of ERbeta, and PKCalpha equals one, imply Abeta
equals two
False
5 Activation of ERalpha and ERbeta, and PKCalpha equals
one, imply Abeta equals two
True
6 Activation of ERalpha or ERbeta implies PKCalpha equals
one
False
7 PKCalpha does not equal one until estrogen equals one True
8 PKCalpha equals one implies Abeta equals two False
9 Activation of ERalpha implies NEP equals three False
10 Activation of ERalpha and ERbeta implies NEP equals three True
11 NEP equals three implies Abeta equals two False
12 PKCalpha equals one and NEP equals three imply Abeta
equals two
True
13 Abeta does not equal two until PKCalpha equals one and
NEP equals three
True
Each row lists a proposition and its logical value (true or false). The row numbers
appear in the leftmost column.
(where ⇒ is the logical connector “implies”). This proposition
states that Abeta is at level 2 only if ERalpha is activated. This
is false under the conditions of the analysis (Row 1 of Table 3),
meaning that other actions of estrogen besides activation of
ERalpha are necessary to keep Abeta at level 2.
The first five rows in Table 3 lists a set of propositions and their
values that ends with the proposition (ERaACT ∧ ERbACT ∧
PKCeq1) ⇒ AbEQ2 (where ∧ is the logical connector “and”).
This proposition states that Abeta is at level 2 only if ERalpha
and ERbeta are activated and PKCalpha is at level 1. This state-
ment is true but the previous propositions, whose antecedents are
a conjunction (i.e., joined by “and”) of only two of the three prop-
erties in this antecedent, are all false (Rows 2 through 5 of Table 3).
This means that Abetawill stay at level 2 only if estrogen acti-
vates ERalpha and ERbeta and brings PKCalpha to level 1
(i.e., all three of the functions of estrogen in the model are
necessary).
Because PKCα activity is increased by estrogen directly (see
Materials and Methods), it is useful to make sure that PKCalpha
activity cannot be increased indirectly via ERalpha or ERbeta
activation in the model. The proposition (ERaACT ∨ ERbACT)
⇒ PKCeq1 (where∨ is the logical connector “or”) is false, mean-
ing that neither ERaACT nor ERbACT activation is sufficient to
raise the level of PKCalpha to 1 (Row 6 of Table 3). The proposi-
tion∼ PKCeq1 U estEQ1 states that PKCalpha is not 1 until
estrogen is present (estEQ1 is the property that estrogen is 1,
and ∼ and U are the temporal-logic connectors “not” and “until,”
respectively). This proposition is true, and the two propositions
together prove estrogen raises the level of PKCalpha, but not
via activation of ERalpha or ERbeta (Rows 6 and 7 of Table 3).
The temporal-logic analysis so far reveals an important differ-
ence between administration of estrogen and ERalphaAg:
estrogen, but not ERalphaAg, raises the activity level of
PKCalpha. Perhaps it is the increase in PKCalpha activity that
allows estrogen to keep Abeta at the normative level 2 while
ERalphaAg fails to do so? This question can be answered by
checking the value of the proposition PKCeq1⇒AbEQ2, which
states that Abeta is 2 only if PKCalpha is 1. This proposition is
false, meaning that PKCalpha at level 1 is not sufficient to keep
Abeta at level 2 (Row 8 of Table 3).
Another difference between the effects of administration of
estrogen and ERalphaAg concerns NEP. Expression of the
enzyme NEP, which degrades Aβ, is upregulated by activation of
ERα or ERβ, and upregulation by both receptors is additive (see
Materials and Methods). In the model, estrogen, which acti-
vates both ERalpha and ERbeta, raisesNEP to 3, and it is useful
to check to ensure that ERalphaAg cannot raise NEP to 3 by
itself. The proposition ERaACT ⇒ NEPeq3 (where NEPeq3is
the property that NEP is at level 3) is false (Row 9 of Table 3).
This means that activation of ERalpha alone is not sufficient
to raise NEP to level 3. The proposition (ERaACT ∧ ERbACT)
⇒ NEPeq3 is true (Row 10 of Table 3), meaning that NEP
reaches level 3 only if both ERalpha and ERbeta are activated.
Thus, estrogen raises NEP to level 3 because it activates both
ERalpha and ERbeta.
Perhaps it is this increase in NEP expression that allows
estrogen to keep Abeta at the normative level 2 while
ERalphaAg fails to do so? This question can be answered by
checking the proposition NEPeq3 ⇒ AbEQ2, which states that
Abeta is 2 only if NEP is 3. This proposition is false (Row
11 of Table 3), meaning that NEP at level 3 is not sufficient to
keep Abeta at level 2. This leads to the question of whether the
increases due to estrogen of PKCalpha and NEP are both
necessary to keep Abeta at its normative level in the presence
of CVD. This question can be answered by checking the values of
two further propositions. The proposition(PKCeq1∧NEPeq3)
⇒ AbEQ2 is true, meaning that Abeta stays at level 2 only
if PKCalpha is 1 and NEP is 3. The proposition ∼ AbEQ2
U (PKCeq1 ∧ NEPeq3) is also true, meaning that Abeta is
not 2 until PKCalpha is 1 and NEP is 3 (Rows 12 and 13 of
Table 3). These two propositions together prove that Abeta is
not at level 2 unless PKCalpha is at level 1 and NEP is at level
3. The temporal-logic analysis in this subsection suggests that,
under conditions of low estrogen and incipient CVD, and with
co-administration of an NSAID that promotes PPAR expression
and a compound that blocks HIF, administration of estrogen itself
would be more effective in lowering Aβ than administration of an
ERα agonist.
DISCUSSION
The main finding of the simulations and analysis presented in
Results is that, under conditions of very low estrogen and incipient
CVD, the level of Aβ could be reduced, possibly to normative levels,
with a combination of an NSAID that promotes PPAR expres-
sion, a compound that blocks HIF, and estrogen itself. The model
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suggests that estrogen would provide the main benefit, reducing
Aβ directly (e.g., by enhancing NEP expression) and indirectly by
reducing inflammation and OS (e.g., by enhancing SOD expres-
sion), thereby disrupting pathological processes that contribute
to Aβ accumulation. With estrogen itself providing the main
benefit, an NSAID and a HIF-blocker can each provide a small
additional benefit, and these two benefits are additive in com-
bination. The idea of combination estrogen/NSAID/HIF-blocker
therapy for the treatment of AD in post-menopausal women is
plausible.
The usage of estrogen and its derivatives for hormone replace-
ment therapy is widespread but its benefits are still hotly debated
(Barlow, 2008; Shifren and Schiff, 2010; Daniel, 2012; Mar-
joribanks et al., 2012; Moyer and On Behalf of the U.S. Pre-
ventive Services Task Force, 2012; Nelson et al., 2012). A con-
sensus seeming to emerge is that estrogen replacement ther-
apy may provide some neuroprotection if initiated soon after
menopause.
The usage of estrogen is dwarfed by that of NSAIDs, which are
among the most commonly used over-the-counter drugs. While
epidemiological studies show that NSAIDs reduce AD risk, clini-
cal trials testing NSAID efficacy in AD patients have not yielded
positive results (Heneka et al., 2011). However, available evidence
does not rule out the possibility that NSAIDs could be effective
in combination with estrogen. NSAIDs potentially may reduce Aβ
via several mechanisms including upregulation of PPAR expres-
sion (Sastre et al., 2006), and modulation of γ-secretase activity in
such a way that APP processing byγ-secretase is reduced more than
processing by γ-secretase of its other substrates (De Strooper et al.,
2010). The model represents only the PPAR-upregulating function
of NSAIDs and suggests that it may augment PPAR upregula-
tion due to estrogen, thereby providing additional benefit. The
γ-secretase-modulating role of NSAIDs could also provide some
benefit, but that was not explored in this model.
Compounds exist that block HIF. One such is cilnidipine, which
is also a calcium-channel blocker but it blocks HIF synthesis inde-
pendently of its effects on ion channels (Oda et al., 2009). The
discovery that cilnidipine blocks HIF synthesis raises the possi-
bility that pharmaceuticals that specifically block HIF could be
developed. The model suggests that such drugs would be useful
for the prevention of AD, especially in combination with estrogen
and NSAIDs. Compounds also exist that block the activation of
caspase-3 (Dave et al., 2003), but the model suggests that blocking
caspase-3 would be ineffective if co-administered with estrogen
because estrogen already prevents caspase-3 activation directly, by
increasing seladin-1 expression, and indirectly by reducing OS in
the model.
The model also suggests that, in terms of reducing the level
of Aβ, agonists of ERα would be substantially more effective than
agonists of ERβ. Among the differential effects of ERα or ERβ acti-
vation, two are represented in the model: ERα activation increases
seladin-1 expression but ERβ activation does not (Benvenuti et al.,
2005), and ERα activation increases apoE expression while ERβ
activation suppresses it (Wang et al., 2006). The three most com-
mon apoE isoforms are apoE2, apoE3, and apoE4, and the apoE4
isoform is associated with increased risk of AD (Saunders, 2000).
These findings suggest that administration of an ERβ agonist could
be the preferred treatment in carriers of the apoE4 allele (Wang
et al., 2006). Otherwise, the model suggests that ERα should pro-
duce a dramatic reduction in Aβ by preventing it from triggering
OS, which leads to further Aβ accumulation. The model also sug-
gests that estrogen itself would be more effective than ERα agonists
because estrogen, by activating both ERα and ERβ, brings NEP
to a higher level than specific agonists of either receptor could
do (Liang et al., 2010), and because estrogen directly activates
PKCα (Alzamora et al., 2007), which in turn shifts APP processing
away from the Aβ pathway by activating α-secretase (Cisse et al.,
2011). The combined effects of estrogen alone prevent OS and also
prevent the activation of cytokines.
In pulling many strands of data together, the model provides
potential new insights into the contribution that estrogen makes
to Aβ regulation. Its two main predictions are that, under condi-
tions of low estrogen and incipient CVD, estrogen should reduce
Aβ levels more than specific agonists either of ERα or ERβ, and
NSAIDs and/or compounds that block HIF should provide addi-
tional benefit in combination with estrogen. However, any of the
input/output configurations presented in Tables 1 and 2 could
be taken as predictions of the model. These predictions could
be tested experimentally using essentially the same in vitro and
in vivo (mainly mouse) methods that were used to generate the
data represented in the model. The results could be used to ver-
ify or correct the model, and verified predictions would provide
avenues for development of new pharmacological strategies for
the prevention and treatment of AD.
The model aggregates much of the current literature on Aβ
regulation and the contribution of estrogen, but it is clear that
the model could be expanded to include many more relevant
interactions. Even still, at about 80 molecular interactions, the
computational model could potentially generate a wide range of
predictions, and far more than could be generated without it. The
model demonstrates how declarative programming can be used to
represent, simulate, and analyze large amounts of data on com-
plex neurodegenerative processes and to generate experimentally
testable predictions, and it stakes its claim as the starting point
of a process in which model predictions are tested, the results are
used to correct and extend the model, more predictions are gener-
ated and tested, and the process continues. The result is a model of
ever increasing accuracy and explanatory power that provides ever
more insight into the complex system of molecular interactions
that underlie AD.
The model also illustrates the power of computation in repre-
senting and reasoning about complex neurodegenerative diseases,
and clearly shows how it could be used to derive hypotheses
concerning the potential benefits of multi-drug therapies. The
approach is consistent with the general idea that complex prob-
lems require complex solutions, and that multifactorial disease
processes such as neurodegenerative diseases should be combat-
ted simultaneously on multiple fronts. Computational modeling
of neurodegenerative disease processes using declarative pro-
gramming provides a powerful methodology to aggregate data
and search for potentially effective drug combinations. Support
for expanding the model computationally and testing it exper-
imentally should be provided. The current model is a call to
arms.
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